(Q34610829)

English

An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Argentina Leon

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Alain Nguyen

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Julie Letsinger

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

John Koo

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

1 April 2007

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

617-632

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Psoriasis--epidemiology and clinical spectrum

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

The economic impact of psoriasis increases with psoriasis severity.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Psoriasis causes as much disability as other major medical diseases

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Update on the mechanisms and efficacy of biological therapies for psoriasis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

The Goeckerman regimen in two psoriasis day care centers

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

A 12-month treatment of severe psoriasis with acitretin: Results of a Canadian open multicenter study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Cutaneous and ocular side-effects of oral photochemotherapy: results of an 8-year follow-up study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Treatment of psoriasis. Part 2. Systemic therapies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Ciclosporin in psoriasis clinical practice: an international consensus statement

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Retrospective study of the efficacy of narrowband UVB and acitretin.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Duration of remission of psoriasis therapies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Phototherapy for psoriasis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.617

21 January 2018

Identifiers

10.1517/14656566.8.5.617

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34610829&oldid=1991459363"